Pantoprazole Attenuates MAPK (ERK1/2, JNK, p38)-NF-κB and Apoptosis Signaling Pathways after Renal

Michael A Fawzy1, Sherif A Maher2, Sally M Bakkar3

  • 1Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.

Insights

Pantoprazole effectively mitigates kidney injury caused by ischemia/reperfusion (IRI) by reducing inflammation and apoptosis. Multiple doses showed greater protective effects against renal damage in rats.

Area of Science:

  • Nephrology
  • Pharmacology
  • Molecular Biology

Background:

  • Kidney ischemia/reperfusion injury (IRI) is a primary cause of acute kidney dysfunction.
  • Understanding the molecular mechanisms of IRI is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the molecular effects of pantoprazole on renal IRI in a rat model.
  • To elucidate the protective mechanisms of pantoprazole against IRI-induced kidney damage.

Main Methods:

  • Assessment of biochemical parameters and oxidative stress markers.
  • Quantification of proinflammatory cytokines using ELISA.
  • Analysis of gene and protein expression via qRT-PCR and Western blot.
  • Histopathological examination of kidney tissue.

Main Results:

  • IRI induced significant kidney damage, elevated serum creatinine, urea nitrogen, and malondialdehyde.
  • IRI led to increased levels of TNF-α, IL-6, IL-1β, and upregulated NF-κB, JNK1/2, ERK1/2, p38, and cleaved caspase-3.
  • Pantoprazole treatment ameliorated IRI-induced damage, reduced inflammation, and modulated apoptosis-related gene/protein expression (Bax, Bcl-2).
  • Multiple doses of pantoprazole demonstrated superior protective effects compared to a single dose.

Conclusions:

  • Pantoprazole effectively diminishes renal IRI by suppressing apoptosis.
  • Pantoprazole attenuates pro-inflammatory cytokine levels and inhibits the MAPK (ERK1/2, JNK, p38)-NF-κB signaling pathway.
  • The findings highlight pantoprazole's therapeutic potential in managing kidney IRI.